Medical device and MedTech insights, news, tips and more

FDA and CDC Drawing Up Plan to Restart Routine Facility Inspections

May 14, 2020

FDA Logo

Amid the coronavirus outbreak reaching pandemic level in March, FDA stopped routine inspections of domestic and international facilities. Under the revised policy, the agency would perform inspections seen as “mission critical” while relying on off-site monitoring and the commitment of companies to quality in the absence of in-person regulatory oversight to maintain standards during the public health emergency.

Although parts of the U.S. economy are starting to reopen, the restrictions imposed by FDA in March are still in place. Hahn said the postponement of on-site inspections “will continue as local, national and international conditions warrant.”

The agency is working to get its inspection program going again, though. In partnership with CDC, Hahn and his colleagues are developing “a process that would govern how and where to return to on-site facility surveillance inspections,” the FDA commissioner said. The process will adopt the criteria for resuming activities detailed in the White House strategy for reopening the U.S. economy. 

FDA acknowledged that companies may be suffering disruptions in a guidance document updated on the same day as Hahn’s statement. The guidance details how manufacturers of all products regulated by FDA should handle postmarketing adverse event reporting if they lack the capacity to comply with regulations that are in place in normal times. 

The revised version published Monday introduces further tweaks. Throughout the text, FDA has removed references to “normal” reporting processes, replacing them with the phrase “reporting as required by statute and regulation.” 

See Full Article: FDA, CDC drawing up plan to restart routine facility inspections | MedTech Dive

Written by: Nick Paul Taylor

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?

Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.